FORSTEO повишава КМП на тазобедрената област (3, 6%) в сравнение с алендронат (2, 2%) (p < 0, 01), както и на бедрената шийка (3, 7%) в сравнение с алендронат (2, 1%) (p < 0, 05).
FORSTEO increased BMD at the total hip (3.6%) compared with alendronate (2.2%) (p < 0.01), as well as at the femoral neck (3.7%) compared with alendronate (2.1%) (p < 0.05).